Cipla Questions Patentability Of Roche’s Tarceva In Ongoing Dispute

MUMBAI - The long drawn patent fight in India between Swiss drug giant Roche and Indian generics company Cipla over lung cancer drug Tarceva (erlotinib) is poised for an interesting turn